+
データを開く
-
基本情報
| 登録情報 | データベース: PDB / ID: 3oiv | ||||||
|---|---|---|---|---|---|---|---|
| タイトル | H-RasG12V with allosteric switch in the "off" state | ||||||
要素 | GTPase HRas | ||||||
キーワード | SIGNALING PROTEIN / ONCOGENE GTP-BINDING NUCLEOTIDE-BINDING | ||||||
| 機能・相同性 | 機能・相同性情報phospholipase C activator activity / GTPase complex / oncogene-induced cell senescence / positive regulation of miRNA metabolic process / positive regulation of ruffle assembly / T-helper 1 type immune response / positive regulation of wound healing / defense response to protozoan / regulation of neurotransmitter receptor localization to postsynaptic specialization membrane / Signaling by RAS GAP mutants ...phospholipase C activator activity / GTPase complex / oncogene-induced cell senescence / positive regulation of miRNA metabolic process / positive regulation of ruffle assembly / T-helper 1 type immune response / positive regulation of wound healing / defense response to protozoan / regulation of neurotransmitter receptor localization to postsynaptic specialization membrane / Signaling by RAS GAP mutants / Signaling by RAS GTPase mutants / Activation of RAS in B cells / RAS signaling downstream of NF1 loss-of-function variants / SOS-mediated signalling / Activated NTRK3 signals through RAS / Activated NTRK2 signals through RAS / positive regulation of protein targeting to membrane / SHC1 events in ERBB4 signaling / adipose tissue development / Signalling to RAS / Activated NTRK2 signals through FRS2 and FRS3 / SHC-related events triggered by IGF1R / Schwann cell development / Estrogen-stimulated signaling through PRKCZ / SHC-mediated cascade:FGFR3 / MET activates RAS signaling / SHC-mediated cascade:FGFR2 / Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants / Signaling by PDGFRA extracellular domain mutants / SHC-mediated cascade:FGFR4 / PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases / Erythropoietin activates RAS / SHC-mediated cascade:FGFR1 / Signaling by FGFR4 in disease / FRS-mediated FGFR3 signaling / Signaling by FLT3 ITD and TKD mutants / FRS-mediated FGFR2 signaling / FRS-mediated FGFR4 signaling / FRS-mediated FGFR1 signaling / p38MAPK events / Signaling by FGFR3 in disease / protein-membrane adaptor activity / Tie2 Signaling / Signaling by FGFR2 in disease / myelination / EPHB-mediated forward signaling / GRB2 events in EGFR signaling / SHC1 events in EGFR signaling / Signaling by FLT3 fusion proteins / FLT3 Signaling / Signaling by FGFR1 in disease / EGFR Transactivation by Gastrin / NCAM signaling for neurite out-growth / CD209 (DC-SIGN) signaling / Downstream signal transduction / GRB2 events in ERBB2 signaling / intrinsic apoptotic signaling pathway / Insulin receptor signalling cascade / Ras activation upon Ca2+ influx through NMDA receptor / SHC1 events in ERBB2 signaling / Constitutive Signaling by Overexpressed ERBB2 / Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants / animal organ morphogenesis / VEGFR2 mediated cell proliferation / small monomeric GTPase / positive regulation of epithelial cell proliferation / regulation of actin cytoskeleton organization / positive regulation of JNK cascade / FCERI mediated MAPK activation / RAF activation / Signaling by ERBB2 TMD/JMD mutants / cellular response to gamma radiation / Signaling by SCF-KIT / Constitutive Signaling by EGFRvIII / Signaling by high-kinase activity BRAF mutants / regulation of long-term neuronal synaptic plasticity / MAP2K and MAPK activation / Signaling by ERBB2 ECD mutants / Signaling by ERBB2 KD Mutants / positive regulation of type II interferon production / endocytosis / positive regulation of fibroblast proliferation / chemotaxis / Regulation of RAS by GAPs / RAS processing / Negative regulation of MAPK pathway / Signaling by RAF1 mutants / Signaling by moderate kinase activity BRAF mutants / Paradoxical activation of RAF signaling by kinase inactive BRAF / Signaling downstream of RAS mutants / GDP binding / cellular senescence / Signaling by BRAF and RAF1 fusions / insulin receptor signaling pathway / DAP12 signaling / T cell receptor signaling pathway / MAPK cascade / regulation of cell population proliferation / Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants / G protein activity 類似検索 - 分子機能 | ||||||
| 生物種 | Homo sapiens (ヒト) | ||||||
| 手法 | X線回折 / シンクロトロン / 分子置換 / 解像度: 1.837 Å | ||||||
データ登録者 | Buhrman, G. / Mattos, C. | ||||||
引用 | ジャーナル: J.Biol.Chem. / 年: 2011タイトル: Allosteric Modulation of Ras-GTP Is Linked to Signal Transduction through RAF Kinase. 著者: Buhrman, G. / Kumar, V.S. / Cirit, M. / Haugh, J.M. / Mattos, C. | ||||||
| 履歴 |
|
-
構造の表示
| 構造ビューア | 分子: Molmil Jmol/JSmol |
|---|
-
ダウンロードとリンク
-
ダウンロード
| PDBx/mmCIF形式 | 3oiv.cif.gz | 52.8 KB | 表示 | PDBx/mmCIF形式 |
|---|---|---|---|---|
| PDB形式 | pdb3oiv.ent.gz | 37 KB | 表示 | PDB形式 |
| PDBx/mmJSON形式 | 3oiv.json.gz | ツリー表示 | PDBx/mmJSON形式 | |
| その他 | その他のダウンロード |
-検証レポート
| 文書・要旨 | 3oiv_validation.pdf.gz | 769.7 KB | 表示 | wwPDB検証レポート |
|---|---|---|---|---|
| 文書・詳細版 | 3oiv_full_validation.pdf.gz | 771.8 KB | 表示 | |
| XML形式データ | 3oiv_validation.xml.gz | 10.7 KB | 表示 | |
| CIF形式データ | 3oiv_validation.cif.gz | 14.7 KB | 表示 | |
| アーカイブディレクトリ | https://data.pdbj.org/pub/pdb/validation_reports/oi/3oiv ftp://data.pdbj.org/pub/pdb/validation_reports/oi/3oiv | HTTPS FTP |
-関連構造データ
-
リンク
-
集合体
| 登録構造単位 | ![]()
| |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 |
| |||||||||||||||||||||||||||
| 2 | ![]()
| |||||||||||||||||||||||||||
| 単位格子 |
| |||||||||||||||||||||||||||
| Components on special symmetry positions |
|
-
要素
-タンパク質 , 1種, 1分子 A
| #1: タンパク質 | 分子量: 18917.271 Da / 分子数: 1 / 変異: G12V / 由来タイプ: 組換発現 / 由来: (組換発現) Homo sapiens (ヒト) / 遺伝子: HRAS, HRAS1 / プラスミド: pET21 / 発現宿主: ![]() |
|---|
-非ポリマー , 5種, 156分子 








| #2: 化合物 | ChemComp-GNP / | ||||
|---|---|---|---|---|---|
| #3: 化合物 | ChemComp-CA / | ||||
| #4: 化合物 | | #5: 化合物 | #6: 水 | ChemComp-HOH / | |
-実験情報
-実験
| 実験 | 手法: X線回折 / 使用した結晶の数: 1 |
|---|
-
試料調製
| 結晶 | マシュー密度: 2.61 Å3/Da / 溶媒含有率: 52.94 % |
|---|---|
| 結晶化 | 温度: 298 K / 手法: シッティングドロップ法 / pH: 7.5 詳細: 200 Mm Calcium Chloride, 20 % PEG 3350, pH 7.5, sitting drop, temperature 298K |
-データ収集
| 回折 | 平均測定温度: 100 K | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 放射光源 | 由来: シンクロトロン / サイト: APS / ビームライン: 22-ID / 波長: 1 Å | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 検出器 | タイプ: MARMOSAIC 300 mm CCD / 検出器: CCD | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 放射 | モノクロメーター: CRYSTAL / プロトコル: SINGLE WAVELENGTH / 単色(M)・ラウエ(L): M / 散乱光タイプ: x-ray | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 放射波長 | 波長: 1 Å / 相対比: 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 反射 | 解像度: 1.84→50 Å / Num. all: 17438 / Num. obs: 17438 / % possible obs: 99.7 % / Observed criterion σ(F): 0.1 / Observed criterion σ(I): 0.1 / 冗長度: 10.1 % / Rmerge(I) obs: 0.131 / Χ2: 0.958 / Net I/σ(I): 5.6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 反射 シェル |
|
-位相決定
| 位相決定 | 手法: 分子置換 |
|---|
-
解析
| ソフトウェア |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 精密化 | 構造決定の手法: 分子置換 / 解像度: 1.837→26.404 Å / Occupancy max: 1 / Occupancy min: 0.5 / SU ML: 0.19 / σ(F): 0.13 / 立体化学のターゲット値: ML
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 溶媒の処理 | 減衰半径: 0.9 Å / VDWプローブ半径: 1.11 Å / 溶媒モデル: FLAT BULK SOLVENT MODEL / Bsol: 60.667 Å2 / ksol: 0.4 e/Å3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 原子変位パラメータ | Biso max: 67.95 Å2 / Biso mean: 19.2325 Å2 / Biso min: 5.16 Å2
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 精密化ステップ | サイクル: LAST / 解像度: 1.837→26.404 Å
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 拘束条件 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LS精密化 シェル | Refine-ID: X-RAY DIFFRACTION / Total num. of bins used: 10
|
ムービー
コントローラー
万見について




Homo sapiens (ヒト)
X線回折
引用











PDBj


























